Post-Market Study of Low-flow ECCO2R Using PrismaLung+ : A Post-Market Study of Performance and Safety of Low-flow Extracorporeal Carbon Dioxide Removal Using PrismaLung+ in Patients With Mild to Moderate Acute Respiratory Distress Syndrome

PrismaLung+ is indicated to provide extracorporeal carbon dioxide removal (ECCO2R) as a stand-alone therapy or in combination with continuous renal replacement therapy (CRRT). This study is intended for patients with increased levels of Carbon Dioxide (CO2) in their blood and ≥ 18 years old, and will treat patients with mild or moderate acute respiratory distress syndrome (ARDS) using PrismaLung+. The study will assess tidal volume reduction and confirm the safety of PrismaLung+..

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

ClinicalTrials.gov - (2023) vom: 02. Aug. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Acute Lung Injury
Recruitment Status: Recruiting
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Study Type: Interventional
Syndrome

Anmerkungen:

Source: Link to the current ClinicalTrials.gov record., First posted: November 5, 2020, Last downloaded: ClinicalTrials.gov processed this data on August 09, 2023, Last updated: August 09, 2023

Study ID:

NCT04617093
BXU542357

Veröffentlichungen zur Studie:

fisyears:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG003567508